{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T22:12:40Z","timestamp":1794867160173,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF-223-2018-10020I"],"award-info":[{"award-number":["HHSF-223-2018-10020I"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["GS-10F-0133S"],"award-info":[{"award-number":["GS-10F-0133S"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128459","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:49:59Z","timestamp":1773481799000},"page":"128459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety monitoring of health outcomes following RSVPreF3\u00a0+\u00a0AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65\u00a0years and older in the United States, 2023\u20132024"],"prefix":"10.1016","volume":"79","author":[{"given":"Patricia C.","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry T.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiruo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tainya C.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128459_bb0005","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0010","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0015","series-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices \u2014 United States","first-page":"793","volume":"72","author":"Melgar","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128459_bb0020","author":"United States (U.S.) Food and Drug Administration (FDA)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0025","article-title":"Food and Drug Administration (FDA)","author":"United States (U.S.)","year":"2025","journal-title":"ABRYSVO"},{"key":"10.1016\/j.vaccine.2026.128459_bb0030","article-title":"Food and Drug Administration (FDA)","author":"United States (U.S.)","year":"2024","journal-title":"MRESVIA"},{"key":"10.1016\/j.vaccine.2026.128459_bb0035","author":"United States (U.S.) Food and Drug Administration (FDA)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0040","author":"United States (U.S.) Food and Drug Administration (FDA)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0045","author":"Biologics Effectiveness and Safety (BEST) Initiative"},{"key":"10.1016\/j.vaccine.2026.128459_bb0050","author":"Centers for Medicare & Medicaid Services (CMS)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0055","author":"Centers for Disease Control and Prevention (CDC)"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128459_bb0060","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/jama.2024.1059","article-title":"Stroke risk after COVID-19 bivalent vaccination among US older adults","volume":"331","author":"Lu","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128459_bb0065","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.vaccine.2026.128459_bb0070","doi-asserted-by":"crossref","unstructured":"Cox C, Li X, Model-based estimation of the attributable risk: a loglinear approach. Comput Stat Data Anal, 2012. 56(12): p. 4180\u20134189. DOI: https:\/\/doi.org\/10.1016\/j.csda.2012.04.017. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23049150\/.","DOI":"10.1016\/j.csda.2012.04.017"},{"key":"10.1016\/j.vaccine.2026.128459_bb0075","series-title":"Encyclopedia of Biostatistics","article-title":"Delta method","author":"Cox","year":"2005"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128459_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/biostatistics\/kxn013","article-title":"Case series analysis for censored, perturbed, or curtailed post-event exposures","volume":"10","author":"Farrington","year":"2009","journal-title":"Biostatistics"},{"issue":"494","key":"10.1016\/j.vaccine.2026.128459_bb0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1198\/jasa.2011.ap10108","article-title":"Self-controlled case series analysis with event-dependent observation periods","volume":"106","author":"Farrington","year":"2026","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.vaccine.2026.128459_bb0090","doi-asserted-by":"crossref","unstructured":"Shoaibi A, Lloyd PC, Wong HL, et al., Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: two self-controlled studies in the U.S. Vaccine 41(32): p. 4666\u20134678.2026 DOI: https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.014. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X23006825?via%3Dihub#m0005.","DOI":"10.1016\/j.vaccine.2023.06.014"},{"issue":"38","key":"10.1016\/j.vaccine.2026.128459_bb0095","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1016\/j.vaccine.2021.08.004","article-title":"ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare","volume":"39","author":"Goud","year":"2026","journal-title":"Vaccine"},{"issue":"50","key":"10.1016\/j.vaccine.2026.128459_bb0100","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1016\/j.vaccine.2013.10.033","article-title":"Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic a\/H1N1 (H1N1pdm09) vaccine","volume":"31","author":"Rouleau","year":"2026","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128459_bb0105","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.vaccine.2024.04.051","article-title":"Assessment of potential adverse events following the 2022\u20132023 seasonal influenza vaccines among U.S. adults aged 65 years and older","volume":"42","author":"Shi","year":"2026","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128459_bb0110","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2026","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128459_bb0115","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2015.07.048","article-title":"Risk of anaphylaxis after vaccination in children and adults","volume":"137","author":"McNeil","year":"2026","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128459_bb0120","article-title":"Safety monitoring of health outcomes following influenza vaccination during the 2023\u20132024 season among U.S. Medicare beneficiaries aged 65 years and older","volume":"53","author":"Lloyd","year":"2026","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128459_bb0125","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/pds.3575","article-title":"Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barr\u00e9 syndrome, encephalitis, or anaphylaxis in the 2012-2013 season","volume":"23","author":"Kawai","year":"2026","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128459_bb0130","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis","volume":"63","author":"Baxter","year":"2026","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.vaccine.2026.128459_bb0135","doi-asserted-by":"crossref","unstructured":"Morgan HJ, Clothier HJ, Sepulveda KG, et al., Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination \u2013 a self-controlled case series analysis. Vaccine 42(9): p. 2212\u20132219. 2026 DOI: doi:https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.099. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X24001269.","DOI":"10.1016\/j.vaccine.2024.01.099"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128459_bb0140","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jama.2025.15405","article-title":"Bivalent RSV prefusion F protein\u2013based vaccine for preventing cardiovascular hospitalizations in older adults: a prespecified analysis of the DAN-RSV trial","volume":"334","author":"Lassen","year":"2025","journal-title":"JAMA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26002677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:54:46Z","timestamp":1781308486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26002677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S0264410X26002677"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128459","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety monitoring of health outcomes following RSVPreF3\u00a0+\u00a0AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65\u00a0years and older in the United States, 2023\u20132024","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128459"}}